An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: AZD2516

Study type: Interventional

Funder types: Industry

Identifiers

NCT00892944

D2080C00009

Details and patient eligibility

About

The purpose of this study is to determine if AZD2516 binds to mGluR5 receptors in the brain. This will then help to make accurate predictions of efficacy and dosing in the future development programme.

Enrollment: 6 estimated patients

Sex: All

Ages: 20 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Normal MRI scan
• Healthy male or non-fertile females
• Body Mass Index (BMI) of ≥19 to ≤28 kg/m2 and weight of ≥50 to ≤100 kg

Exclusion criteria

• History of disease or condition that may interfere with the objectives of the study
• History of previous or ongoing psychiatric disease/condition
• Concomitant medication

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

1

Experimental group

Description:

AZD2516

Treatment:

Drug: AZD2516